Retransplantation for hepatitis C: Implications of different policies

Authors

  • Hugo R. Rosen M.D.

    Corresponding author
    1. Division of Gastroenterology/Hepatology and Liver Transplantation Program, Portland Veterans Affairs Medical Center–Oregon Health Sciences University, Portland
    • Division of Gastroenterology/Hepatology, Portland Veterans Affairs Medical Center, 3710 SW US Veterans Hospital Rd, PO Box 1034, P3-GI, Portland, OR 97207. Telephone: 503-273-5318; FAX: 503-273-5348
    Search for more papers by this author

Abstract

Key Points

1. Approximately 20% of hepatitis C virus (HCV)-positive liver transplant recipients develop evidence of allograft cirrhosis by year 5.

2. The prevalence of HCV infection in patients undergoing retransplantation has significantly increased since 1990.

3. Retransplantation for recurrent HCV is associated with poor long-term survival.

4. Preoperative hyperbilirubinemia (billirubin ≥5 mg/dL) and renal failure predict poor outcome after retransplantation.

5. Retransplantation is the only viable option for patients in whom allografts fail because of recurrent HCV disease.

Ancillary